Patent classifications
C07D313/00
Treprostinil derivative compounds and methods of using same
Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
Treprostinil derivative compounds and methods of using same
Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
Polyketide compound and derivatives thereof for use in the prevention and treatment of a neurological disorder
The present invention relates to a compound, in particular a polyketide compound and derivatives thereof, for use in the prevention and/or treatment of a neurological disorder in an individual. The compound of the invention can promote lactate secretion. A composition comprising the compound of the invention, and a food or food extract enriched with said compound or composition are also provided.
Polyketide compound and derivatives thereof for use in the prevention and treatment of a neurological disorder
The present invention relates to a compound, in particular a polyketide compound and derivatives thereof, for use in the prevention and/or treatment of a neurological disorder in an individual. The compound of the invention can promote lactate secretion. A composition comprising the compound of the invention, and a food or food extract enriched with said compound or composition are also provided.
Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis
The present disclosure provides compositions and methods for metathesizing a first alkenyl or alkynyl group with a second alkenyl or alkynyl group, the composition comprising a ruthenium metathesis catalyst and a photoredox catalyst that is activated by visible light.
ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
Provided are high triplet host compounds based on a multiphenylene macrocycle which comprises at least one group L.sup.1 selected from the group consisting of O, S, Se, BR, BRR′, CRR′, SiRR′, and GeRR′ which links two phenylene groups. Also provided are formulations comprising these compounds. Further provided are OLEDs and related consumer products that utilize these compounds.
ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
Provided are high triplet host compounds based on a multiphenylene macrocycle which comprises at least one group L.sup.1 selected from the group consisting of O, S, Se, BR, BRR′, CRR′, SiRR′, and GeRR′ which links two phenylene groups. Also provided are formulations comprising these compounds. Further provided are OLEDs and related consumer products that utilize these compounds.
CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE
The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE
The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
HIGHLY EFFICIENT SYNTHESIS OF Z-MACROCYCLES USING STEREORETENTIVE, RUTHENIUM-BASED METATHESIS CATALYSTS
A highly efficient, Z-selective ring-closing metathesis system for the formation of macrocycles using a stereoretentive, ruthenium-based catalyst supported by a dithiolate ligand is reported. This catalyst is demonstrated to be remarkably active as observed in initiation experiments showing complete catalyst initiation at −20° C. within 10 min. Using easily accessible diene starting materials bearing a Z-olefin moiety, macrocyclization reactions generated products with significantly higher Z-selectivity in appreciably shorter reaction times, in higher yield, and with much lower catalyst loadings than in previously reported systems. Macrocyclic lactones ranging in size from twelve-membered to seventeen-membered rings are synthesized in moderate to high yields (68-79% yield) with excellent Z-selectivity (95%-99% Z).